Additional Study Information: This is a randomized, double-blinded, placebo-controlled phase 2 study. The purpose of this study is to evaluate the safety and efficacy of Saroglitazar magnesium 2 mg and 4mg versus placebo in the treatment of subjects with Primary Biliary Cholangitis. The research study consists of a Screening Phase (Visits 1 and 2) that lasts up to 42 days, a Treatment Phase (Visits 3 through 7) that will last 112 days, and a safety follow-up 4 weeks later. The research study lasts about 26 weeks.